NDA 219908 is the FDA application for REVTORPYK (gedatolisib). The FDA's Orange Book lists the applicant of record as CELCUITY INC and the first approval on it as Jul 14, 2026. Owner today: Celcuity Inc. (Nasdaq: CELC).
Page updated Nov 19, 2026. FDA records: Drugs@FDA NDA 219908 · Orange Book NDA 219908
| Brand name (FDA) | REVTORPYK Orange Book trade name: REVTORPYK |
|---|---|
| Active ingredient (FDA) | GEDATOLISIB |
| FDA applicant of record | CELCUITY INC FDA Orange Book data files as of Nov 13, 2026 |
|---|---|
| Owner today | Celcuity Inc. (CELC) Source: Celcuity press release, Jul 14, 2026 “MINNEAPOLIS, July 14, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a biotechnology company focused on developing” |
| No. | Trade name | Form; route | Strength | Approved |
|---|---|---|---|---|
| 001 | REVTORPYK | POWDER;INTRAVENOUS | 180MG/VIAL | Jul 14, 2026 |
Drug page: /drug/gedatolisib
Orange Book data: FDA Orange Book data files, as of Nov 13, 2026. Approval dates are the FDA's dates for each product; a later supplement (a new use) does not change them.